PMID- 38146419
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231227
IS  - 1179-1314 (Print)
IS  - 1179-1314 (Electronic)
IS  - 1179-1314 (Linking)
VI  - 15
DP  - 2023
TI  - Retrospective Analysis of the Clinical Characteristics of Patients with Breast 
      Cancer Treated with Telomerase Peptide Immunotherapy Combined with Cytotoxic 
      Chemotherapy.
PG  - 955-966
LID - 10.2147/BCTT.S431333 [doi]
AB  - PURPOSE: Telomerase activation, a critical step in cancer progression, occurs in 
      approximately 95% of breast cancer cases. Telomerase is an attractive therapeutic 
      target for breast cancer owing to its unique expression pattern. GV1001, a 
      telomerase-derived peptide, is loaded onto human leukocyte antigen (HLA) class II 
      antigen-presenting cells and binds to CD4+ T cell activating immune responses. 
      This study aimed to evaluate the effectiveness and safety of co-administration of 
      GV1001 and cytotoxic chemotherapy in patients with heavily-treated metastatic 
      breast cancer. PATIENTS AND METHODS: We analyzed 63 patients with breast cancer 
      who received both GV1001 and cytotoxic chemotherapy. The GV 1001 administration 
      methods involves 0.56 mg intradermal injection three times during the first week, 
      one time at weeks 2, 3, 4, and 6, and then once every 28 days. The primary 
      endpoint of this study was quality of life according to EORTC QLO-C30 and EQ-5D, 
      while the secondary endpoint was the antitumor response according to RECIST 1.1, 
      progression-free survival, overall survival, and toxicity profile. RESULTS: In 34 
      patients with HR+ breast cancer evaluable for tumor response, the disease control 
      rate (DCR) and overall response rate (ORR) were 58.8% and 26.4%, respectively. 
      The DCR and ORR were 66.6% and 28.5% in 21 patients with HER-2+ and 50% and 25% 
      in patients with triple-negative breast cancer (TNBC), respectively. The median 
      progression free survival was 10.4, 8.7, and 5.6 months in HR+, HER-2+, TNBC, 
      respectively. The overall survival was 19.7, 13.2, and 9.4 months for patients 
      with HR+, HER-2+, and TNBC, respectively. Most patients had an improved quality 
      of life with statistically significant differences in some variables. The 
      patients in this study experienced no additional toxicities other than the 
      cytotoxic chemotherapy-associated side effects. CONCLUSION: GV1001 is a 
      relatively safe anticancer vaccine for patients with heavily-treated breast 
      cancer and can to improve the quality of life.
CI  - (c) 2023 Kim et al.
FAU - Kim, Jong Yeup
AU  - Kim JY
AUID- ORCID: 0000-0003-1230-9307
AD  - Department of Biomedical Informatics, College of Medicine, Konyang University, 
      Daejeon, Republic of Korea.
FAU - Yang, Dong Won
AU  - Yang DW
AUID- ORCID: 0009-0002-5307-8971
AD  - Department of Biomedical Informatics, College of Medicine, Konyang University, 
      Daejeon, Republic of Korea.
FAU - Kim, Sangjae
AU  - Kim S
AUID- ORCID: 0009-0003-8877-1060
AD  - Department of Research and Development, Teloid Inc., Los Angeles, CA, 90010, USA.
FAU - Choi, Jong Gwon
AU  - Choi JG
AUID- ORCID: 0000-0002-5085-902X
AD  - Department of Oncology-Hematology, Konyang University Hospital, Daejeon, Republic 
      of Korea.
LA  - eng
PT  - Journal Article
DEP - 20231221
PL  - New Zealand
TA  - Breast Cancer (Dove Med Press)
JT  - Breast cancer (Dove Medical Press)
JID - 101591856
PMC - PMC10749539
OTO - NOTNLM
OT  - GV1001
OT  - breast cancer
OT  - quality of life
OT  - safety
OT  - telomerase
COIS- The authors report no conflicts of interest in this work.
EDAT- 2023/12/26 06:41
MHDA- 2023/12/26 06:42
PMCR- 2023/12/21
CRDT- 2023/12/26 03:41
PHST- 2023/08/28 00:00 [received]
PHST- 2023/12/08 00:00 [accepted]
PHST- 2023/12/26 06:42 [medline]
PHST- 2023/12/26 06:41 [pubmed]
PHST- 2023/12/26 03:41 [entrez]
PHST- 2023/12/21 00:00 [pmc-release]
AID - 431333 [pii]
AID - 10.2147/BCTT.S431333 [doi]
PST - epublish
SO  - Breast Cancer (Dove Med Press). 2023 Dec 21;15:955-966. doi: 
      10.2147/BCTT.S431333. eCollection 2023.